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A total of 138503 women in the Women’s Health Initiative in the United States were followed (for an average of 7.7 years) through
12 September 2005 to examine obesity, especially central obesity in relation to pancreatic cancer (n¼251). Women in the highest
quintile of waist-to-hip ratio had 70% (95% confidence interval 10–160%) excess risk of pancreatic cancer compared with women in
the lowest quintile.
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Pancreatic cancer ranks as the fourth leading cause of cancer death
in the United States (Ekbom and Hunter, 2007). Besides tobacco
smoking and chronic pancreatitis (Lowenfels et al, 1999), little is
known of its aetiology, but recently, increasing evidence has
suggested that obesity is a risk factor (Berrington de Gonzalez
et al, 2003; Larsson et al, 2007). However, in most studies, the
association seems to be weaker in women – who tend to gain
weight more peripherally – than in men, suggesting that central
adiposity may be a stronger risk factor for pancreatic cancer than
body mass index (BMI). Few studies have investigated this aspect
and the findings are inconsistent (Larsson et al, 2005; Sinner et al,
2005; Ansary-Moghaddam et al, 2006; Berrington de Gonzalez
et al, 2006).
We have used the large prospective Women’s Health Initiative
(WHI) study, with measured anthropometric factors, including hip
and waist circumference, to examine the relationship between BMI,
central adiposity, and pancreatic cancer risk.
MATERIALS AND METHODS
Women’s Health Initiative
The WHI, an ongoing, ethnically and geographically diverse,
multi-centre clinical trial (CT) and observational study (OS), was
designed to address some of the major causes of morbidity and
mortality in postmenopausal women. Briefly, a total of 161808
women aged 50–79 years were recruited at 40 clinical centres
throughout the United States from 1 September 1993 through 1998.
The WHI includes three overlapping CT components (hormone
trial, dietary modification trial, and calcium/vitamin D supple-
mentation trial) and an OS. All participants in WHI gave informed
consent and were followed prospectively. Details of the scientific
rationale, eligibility requirements and baseline characteristics of
the participants in the WHI have been published elsewhere (Hays
et al, 2003; Jackson et al, 2003; Langer et al, 2003; Ritenbaugh et al,
2003; Stefanick et al, 2003).
The following participants were excluded from the original
cohort of 161808:14849 with a history of cancer (except non-
melanoma skin cancer) at baseline, 668 with no follow-up, 7491
with missing values of main exposures and confounders (including
weight, height, waist circumference, hip circumference, smoking,
and diabetes), and 297 (0.18%) with waist-to-hip ratio (WHR)
values of beyond 4 s.d. (WHRo0.4 or WHR41.2), leaving 138503
women for analysis.
All exposures in our analyses were collected at baseline for all
participants. During the baseline clinical visit, trained and certified
staff performed anthropometric measurements, including height,
weight, hip and waist circumferences, and blood pressure. Body
mass index was calculated as weight in kilograms divided by the
square of height in metres. Waist circumference at the natural
waist or narrowest part of the torso and hip circumference at the
maximal circumference were measured to the nearest 0.1cm. WHR
was computed as the ratio of these two measurements. Weight
changes during the participant’s adult lives were obtained by self-
report questionnaire, categorized as weight stayed stable (within
10lb), steady gain in weight, lost weight as an adult and kept it off,
and weight has gone up and down again by more than 10lb.
Information on demographic characteristics, medical history,
and personal habits (lifestyle) were obtained by interview or by
self-report using standardized questionnaires including age at
enrolment (o55, 55–59, 60–64, 65–69, 70–74, 75–), smoking
status (never, past, current) with information on how many years
since quitting for past smokers and how many cigarettes smoked
per day for ever smokers, physical activity and history of
hypertension and diabetes while not pregnant.
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yWomen in the CT were followed through regularly scheduled
examinations to ensure timely ascertainment of updated medical
histories. All women in the CT were expected to attend annual
clinical visits, with intermediate 6-month mail, phone or clinical
contacts. The OS participants were contacted annually by mailed
self-administered questionnaires. The completion rate of OS
annual questionnaires was 93–96%. In this analysis, all partici-
pants were followed up until 12 September 2005. Initial reports of
cancer were ascertained by self-administered questionnaires, and
all self-reports of pancreatic cancer were confirmed by review of
medical records, including pathology reports (if a biopsy or
resection was done).
Statistical analyses
The hazard ratio (HR) for pancreatic cancer was estimated using
the Cox proportional hazards model. Different study cohorts
(participation in OS or CTs, and different treatment assignments
for all three CTs) were treated as strata in the model. In the
multivariable models, we adjusted for age, smoking status (never,
former smoking (quitted timeX30 years, 20–29, 10–19, and o10
years), and current smoking (o4, 5–14, 15–24, 25 and more
cigarettes per day)). As diabetes could be in the causal pathway
between obesity and risk, we performed analyses (both adjusted
and unadjusted) for this factor.
We treated anthropometric measures as categorical (in quin-
tiles) variables in the regression models, except BMI which was
categorized (o22, 22–o25, 25–o30, 30–o35, and X35kg m
 2).
Tests for trend were performed by creating a continuous variable
from the medians of the categories. In addition, to eliminate
undiagnosed cases that might have experienced weight loss before
completing the baseline questionnaires, we also performed
analyses that excluded the first 2 years of follow-up. The
proportional assumption was satisfied for all exposure variables
of interest and potential confounding variables based on graphs of
scaled Schoenfeld residuals (Hess, 1995).
RESULTS
As of 12 September 2005 with an average 7.7 years of follow-up,
251 incident cases of pancreatic cancer had been identified.
Characteristics at baseline of selected variables by quintile of WHR
are shown in Table 1. Compared with women with lower WHR,
those with higher WHR were older, non-white, and less educated.
Women with higher WHR were also more likely to be past or
current smokers and tended to smoke more cigarettes per day and
to have quit more recently, to have higher total energy intake, be
less physically active, and have higher prevalence of diabetes and
hypertension. WHR was positively associated with weight, BMI,
waist and hip circumference.
Among the tested anthropometric variables, only WHR was
significantly associated with the risk of pancreatic cancer. After
adjusting for potential confounders, women in the highest quintile
of WHR had 70% (95% CI 10–160%) excess risk compared with
women in the lowest quintile of WHR. When WHR was analyzed
as a continuous variable, risk increased by 27% (95% CI 7–50%)
per 0.1 increase. No association was observed between pancreatic
cancer risk and other anthropometric variables, including height,
BMI, hip circumference, waist circumference, and weight changes
during adult life (Table 2).
Finally, we repeated all the above analyses with the exclusion of
the first 2 years of follow-up; findings remained broadly similar to
Table 1 Baseline characteristics of participants in relation to WHR (quintiles) among 138503 postmenopausal women
a
WHR (quintile, range)
Variable 1 (0.40–0.75) 2 (0.75–0.79) 3 (0.79–0.82) 4 (0.82–0.87) 5 (0.87–1.20)
Total number of women 27707 27694 27736 27651 27715
Age at baseline (mean, years) 61.4 62.7 63.3 63.7 64.2
White, non-Hispanic-ethnicity (%) 86.9 84.3 82.0 79.6 79.6
College graduate or above education (%) 48.1 43.1 38.3 34.9 31.3
Ever smoking (%)
Past 37.6 39.2 40.1 41.1 42.8
Quit o20 years(%) 41.4 44.3 46.5 51.3 54.5
Current 5.0 6.7 7.2 7.8 8.9
X15 cigarettesday
 1 (%) 40.4 43.3 48.5 49.3 53.9
Dietary intake (mean)
Total energy intake (kcalday
 1) 1580 1611 1638 1679 1727
Fruit and vegetable(median servings per day) 4.3 4.2 4.1 3.9 3.9
Physical activity (METs per week) 15.2 13.8 12.3 11.0 9.7
Diabetes mellitus (%) 1.4 2.3 4.0 6.9 14.2
Hypertension (%) 19.4 26.0 32.5 39.5 48.8
Weight (kg, mean) 65.5 69.1 72.8 77.1 81.8
Height (cm, Mean) 162.4 162.0 161.7 161.5 161.5
BMI (kgm
 2, mean) 24.9 26.3 27.8 29.5 31.3
Waist circumference (mean, cm) 73.8 80.2 85.6 91.8 100.8
Hip circumference (mean, cm) 103.3 104.5 106.5 108.7 109.5
WHR (mean) 0.71 0.77 0.80 0.85 0.92
Type of weight change
Steady gain in weight 23.6 30.3 34.4 38.0 39.6
Lost weight and kept it off 4.3 3.0 2.2 1.8 1.4
Weight upon and down (more than 10lb) 27.6 31.0 34.3 37.4 41.1
BMI¼body mass index; MET¼metabolic equivalent tasks; WHR¼waist-to-hip ratio.
aAll comparisons of cohort characteristics by waist-to-hip levels are significantly different,
with Po0.0001 based on w
2 test for categorical variables and analysis of variance (ANOVA) test for continuous variables.
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ythose from the full analyses with RR¼1.6 (95% CI: 1.0–2.6)
comparing women in the highest to the lowest of WHR.
DISCUSSION
In this large prospective study, we observed that central obesity
measured by high WHR, rather than general obesity measured by
high BMI, was associated with an increased risk of developing
pancreatic cancer among postmenopausal women.
Our result is consistent with most earlier studies for central
adiposity and pancreatic cancer (Larsson et al, 2005; Patel et al,
2005; Ansary-Moghaddam et al, 2006; Berrington de Gonzalez
et al, 2006), although not all (Sinner et al, 2005). In particular, the
large prospective European prospective investigation into cancer
and nutrition (EPIC) study (Berrington de Gonzalez et al, 2006)
also observed significant increased risk associated with higher
WHR (HR¼1.24 (1.04–1.48) per 0.1 increase of WHR), but not
with BMI. In fact, there was a weak or no association among
women in all but 4 (Michaud et al, 2001; Calle et al, 2003; Pan et al,
2004; Patel et al, 2005) of the 16 studies published since 2000 on
the association between the risk of pancreatic cancer and BMI that
included women (Coughlin et al, 2000; Gapstur et al, 2000; Nilsen
and Vatten, 2000; Hanley et al, 2001; Michaud et al, 2001; Wolk
et al, 2001; Calle et al, 2003; Pan et al, 2004; Eberle et al, 2005;
Fryzek et al, 2005; Larsson et al, 2005; Patel et al, 2005; Rapp et al,
2005; Sinner et al, 2005; Lin et al, 2007; Nothlings et al, 2007).
The link between obesity and pancreatic cancer – similar to the
plausible mechanism between diabetes and pancreatic cancer –
may arise as a result of elevated fasting and postprandial glucose
concentration, hyperinsulinemia, or both (Everhart and Wright,
1995; Gapstur et al, 2000; Batty et al, 2004; Jee et al, 2005). Many
experimental studies (Pour and Stepan, 1984; Pour et al, 1990;
Schneider et al, 2001; Wang et al, 2003; Hennig et al, 2004) and
Table 2 Age-adjusted and multivariate-adjusted HR of pancreatic cancer by baseline measures of adiposity among 138503 postmenopausal women










1 (100.0–156.4, 153.6) 63 Reference Reference Reference
2 (156.5–160.1, 158.5) 54 1.0 (0.7–1.4) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
3 (160.2–163.4, 161.9) 48 0.9 (0.6–1.3) 0.8 (0.6–1.2) 0.8 (0.6–1.2)
4 (163.5–167.0, 165.1) 43 0.9 (0.6–1.2) 0.8 (0.5–1.1) 0.8 (0.5–1.1)
5 (167.1–212.0, 170.0) 43 0.9 (0.6–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
P (trend) 0.4 0.3 0.3
BMI (kg m
 2)
o22.0 25 0.8 (0.5–1.2) 0.8 (0.5–1.2) 0.8 (0.5–1.2)
22.0–24.9 62 Reference Reference Reference
25.0–29.9 84 0.9 (0.6–1.2) 0.9 (0.6–1.2) 0.9 (0.6–1.2)
30.0–34.9 56 1.2 (0.8–1.7) 1.1 (0.8–1.6) 1.1 (0.7–1.5)
35.0– 24 0.9 (0.6–1.4) 0.9 (0.5–1.4) 0.8 (0.5–1.3)
P (trend) 0.4 0.5 0.9
Hip (cm) quintile (range, median)
1 (40.0–96.9, 93.0) 52 Reference Reference Reference
2 (97.0–101.9, 99.0) 58 1.2 (0.8–1.7) 1.2 (0.8–1.8) 1.2 (0.8–1.8)
3 (102.0–107.1, 104.3) 50 1.0 (0.6–1.4) 1.0 (0.6–1.4) 0.9 (0.6–1.4)
4 (107.1–115.0, 111.0) 42 0.9 (0.6–1.3) 0.9 (0.6–1.3) 0.8 (0.6–1.3)
5 (115.1–200.0, 122.5) 49 1.1 (0.7–1.6) 1.1 (0.7–1.6) 1.0 (0.7–1.5)
P (trend) 0.7 0.6 0.4
Waist (cm) quintile (range, median)
1 (35.0–74.5, 70.5) 41 Reference Reference Reference
2 (74.6–81.0, 78.0) 50 1.2 (0.8–1.7) 1.1 (0.7–1.7) 1.1 (0.7–1.7)
3 (81.1–88.0, 85.0) 46 1.1 (0.7–1.6) 1.0 (0.7–1.6) 1.0 (0.7–1.6)
4 (88.1–97.4, 92.4) 63 1.5 (1.0–2.2) 1.4 (1.0–2.1) 1.4 (0.9–2.0)
5 (97.5–194.2, 105.0) 51 1.3 (0.9–1.9) 1.2 (0.8–1.8) 1.1 (0.7–1.6)
P (trend) 0.1 0.2 0.6
Waist as continuous (per 10cm) 251 1.10 (1.00–1.20) 1.08 (0.98–1.18) 1.05 (0.95–1.15)
WHR quintile (range, median)
1 (0.40–0.75, 0.72) 34 Reference Reference Reference
2 (0.75–0.79, 0.77) 47 1.3 (0.8–2.0) 1.3 (0.8–1.9) 1.2 (0.8–1.9)
3 (0.79–0.82, 0.80) 44 1.2 (0.7–1.8) 1.1 (0.7–1.7) 1.1 (0.7–1.7)
4 (0.82–0.87, 0.84) 48 1.2 (0.8–1.9) 1.2 (0.7–1.8) 1.1 (0.7–1.7)
5 (0.87–1.20, 0.91) 78 2.0 (1.4–3.0) 1.8 (1.2–2.8) 1.7 (1.1–2.6)
P (trend) 0.0003 0.002 0.01
WHR as continuous (per 0.1) 251 1.38 (1.17–1.63) 1.32 (1.12–1.56) 1.27 (1.07–1.50)
Type of weight change
Stable weight 85 Reference Reference Reference
Steady gain in weight 77 0.9 (0.7–1.2) 0.9 (0.7–1.2) 0.9 (0.6–1.2)
Lost weight and kept it off 5 0.7 (0.3–1.6) 0.6 (0.3–1.6) 0.6 (0.3–1.5)
Weight up and down (more than 10lb) 83 1.0 (0.7–1.3) 0.9 (0.7–1.3) 0.9 (0.7–1.2)
CI¼confidence interval; HR¼hazard ratio; WHR¼waist-to-hip ratio.
aAdjusted variables included age, different treatment assignments in clinical trials, and smoking status
(never, former smoking (quitted timeX30years, 20-o30, 10-o20, o10 years), and current smoking (o4, 5–14, 15–24, 25 and more cigarettes per day)).
bFurther adjusted for
diabetes history at baseline.
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yobservational studies (Everhart and Wright, 1995; Gapstur et al,
2000; Huxley et al, 2005; Stolzenberg-Solomon et al, 2005) support
the biological plausibility of higher insulin concentrations and
insulin resistance in promoting pancreatic cancer development. If
the induced insulin resistance is the underlying mechanism
through which obesity increases the risk, then it is not surprising
that we observed a stronger association with WHR abdominal
adiposity than with BMI among postmenopausal women, because
central adiposity is more strongly associated with glucose
intolerance and increased insulin levels (Carey et al, 1997; Van
Pelt et al, 2001; Sierra-Johnson et al, 2004; Tanko et al, 2004). In
addition, the body fat distribution changes significantly following
menopause, with a shift from preferential storage in gluteal/
femoral regions to abdominal depots. Thus, our finding further
suggests that the central adiposity is a better predictor of disease
risk than BMI in postmenopausal women (Van Pelt et al, 2001).
Strengths of our study include the prospective design, the large
size of the cohort, the reasonably large number of cases, the high
prevalence of obesity, including central adiposity, the detailed
information on potential confounders, and the precise measure-
ment of anthropometric factors. Measurement rather than
self-reporting is particularly important for waist and hip
circumferences, which are likely to be reported less accurately
than height and weight. There is a possibility of misclassification
among the cases, given the difficulty in diagnosis of this disease.
However, this misclassification is likely to be non-differential with
respect to anthropometric measurements, which may make our
results conservative. A second possibility was weight loss because
of undiagnosed disease, but results did not change after excluding
the first 2 years of follow-up. It is unlikely that pancreatic cancer
advanced enough to cause weight loss would remain undiagnosed
for more than 2 years.
In conclusion, our large prospective study shows that increased
central adiposity was associated with an increased risk of
developing pancreatic cancer among postmenopausal women.
ACKNOWLEDGEMENTS
The WHI program is funded by the National Heart, Lung, and
Blood Institute, National Institutes of Health, US Department of
Health and Human Services through contracts N01WH22110,
24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119,
32122, 42107-26, 42129-32, and 44221. A short list of WHI
investigators is given in an appendix.
REFERENCES
Ansary-Moghaddam A, Huxley R, Barzi F, Lawes C, Ohkubo T, Fang X, Jee
SH, Woodward M (2006) The effect of modifiable risk factors on
pancreatic cancer mortality in populations of the Asia-Pacific region.
Cancer Epidemiol Biomarkers Prev 15: 2435–2440
Batty GD, Shipley MJ, Marmot M, Smith GD (2004) Diabetes status and
post-load plasma glucose concentration in relation to site-specific cancer
mortality: findings from the original Whitehall study. Cancer Causes
Control 15: 873–881
Berrington de Gonzalez A, Spencer EA, Bueno-de-Mesquita HB,
Roddam A, Stolzenberg-Solomon R, Halkjaer J, Tjonneland A,
Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Boeing H,
Pischon T, Linseisen J, Rohrmann S, Trichopoulou A, Benetou V,
Papadimitriou A, Pala V, Palli D, Panico S, Tumino R, Vineis P,
Boshuizen HC, Ocke MC, Peeters PH, Lund E, Gonzalez CA, Larranaga N,
Martinez-Garcia C, Mendez M, Navarro C, Quiros JR, Tormo MJ,
Hallmans G, Ye W, Bingham SA, Khaw KT, Allen N, Key TJ,
Jenab M, Norat T, Ferrari P, Riboli E (2006) Anthropometry, physical
activity, and the risk of pancreatic cancer in the European prospective
investigation into cancer and nutrition. Cancer Epidemiol Biomarkers
Prev 15: 879–885
Berrington de Gonzalez A, Sweetland S, Spencer E (2003) A meta-analysis
of obesity and the risk of pancreatic cancer. Br J Cancer 89: 519–523
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight,
obesity, and mortality from cancer in a prospectively studied cohort of
US adults. N Engl J Med 348: 1625–1638
Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA,
Speizer FE, Manson JE (1997) Body fat distribution and risk of non-
insulin-dependent diabetes mellitus in women. The Nurse’s Health
Study. Am J Epidemiol 145: 614–619
Coughlin SS, Calle EE, Patel AV, Thun MJ (2000) Predictors of pancreatic
cancer mortality among a large cohort of United States adults. Cancer
Causes Control 11: 915–923
Eberle CA, Bracci PM, Holly EA (2005) Anthropometric factors and
pancreatic cancer in a population-based case–control study in the San
Francisco Bay area. Cancer Causes Control 16: 1235–1244
Ekbom A, Hunter D (2007) Pancreatic cancer. In Textbook of cancer
epidemiology, Adami HO, Hunter D, Trichopoulos D (eds), pp 233–247.
New York: Oxford University Press Inc
Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic
cancer. A meta-analysis. JAMA 273: 1605–1609
Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH (2005)
The association of body mass index and pancreatic cancer in
residents of southeastern Michigan, 1996–1999. Am J Epidemiol 162:
222–228
Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A (2000)
Abnormal glucose metabolism and pancreatic cancer mortality. JAMA
283: 2552–2558
Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y (2001) Physical activity,
anthropometric factors and risk of pancreatic cancer: results from the
Canadian enhanced cancer surveillance system. Int J Cancer 94: 140–147
Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw
JE (2003) The Women’s Health Initiative recruitment methods and
results. Ann Epidemiol 13: S18–S77
Hennig R, Ding XZ, Adrian TE (2004) On the role of the islets of
Langerhans in pancreatic cancer. Histol Histopathol 19: 999–1011
Hess KR (1995) Graphical methods for assessing violations of the
proportional hazards assumption in Cox regression. Stat Med 14:
1707–1723
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F,
Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-
analysis of 36 studies. Br J Cancer 92: 2076–2083
Jackson RD, LaCroix AZ, Cauley JA, McGowan J (2003) The Women’s
Health Initiative calcium/vitamin D trial: overview and baseline
characteristics of participants. Ann Epidemiol 13: S98–S106
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum
glucose level and cancer risk in Korean men and women. JAMA 293:
194–202
Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M (2003)
The Women’s Health Initiative Observational Study: baseline character-
istics of participants and reliability of baseline measures. Ann Epidemiol
13: S107–S121
Larsson SC, Orsini N, Wolk A (2007) Body mass index and pancreatic
cancer risk: a meta-analysis of prospective studies. Int J Cancer 120:
1993–1998
Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A (2005)
Overall obesity, abdominal adiposity, diabetes and cigarette smoking in
relation to the risk of pancreatic cancer in two Swedish population-based
cohorts. Br J Cancer 93: 1310–1315
Lin Y, Kikuchi S, Tamakoshi A, Yagyu K, Obata Y, Inaba Y, Kurosawa M,
Kawamura T, Motohashi Y, Ishibashi T, JACC Study Group (2007)
Obesity, physical activity and the risk of pancreatic cancer in a large
Japanese cohort. Int J Cancer 120(12): 2665–2671
Lowenfels AB, Maisonneuve P, Lankisch PG (1999) Chronic pancreatitis
and other risk factors for pancreatic cancer. Gastroenterol Clin North Am
28: 673–685, x
Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs
CS (2001) Physical activity, obesity, height, and the risk of pancreatic
cancer. JAMA 286: 921–929
Obesity and pancreatic cancer risk
J Luo et al
530












yNilsen TI, Vatten LJ (2000) A prospective study of lifestyle factors and the
risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes
Control 11: 645–652
Nothlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Kolonel LN
(2007) Body mass index and physical activity as risk factors for pancreatic
cancer: the Multiethnic Cohort Study. Cancer Causes Control 18: 165–175
Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y (2004) Association of
obesity and cancer risk in Canada. Am J Epidemiol 159: 259–268
Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE (2005)
Obesity, recreational physical activity, and risk of pancreatic cancer in a
large US cohort. Cancer Epidemiol Biomarkers Prev 14: 459–466
Pour PM, Kazakoff K, Carlson K (1990) Inhibition of streptozotocin-
induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced
pancreatic exocrine tumors in Syrian hamsters by exogenous insulin.
Cancer Res 50: 1634–1639
Pour PM, Stepan K (1984) Modification of pancreatic carcinogenesis in the
hamster model. VIII. Inhibitory effect of exogenous insulin. J Natl Cancer
Inst 72: 1205–1208
Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G,
Oberaigner W, Weiland SK (2005) Obesity and incidence of cancer: a large
cohort study of over 145000 adults in Austria. Br J Cancer 93: 1062–1067
Ritenbaugh C, Patterson RE, Chlebowski RT, Caan B, Fels-Tinker L,
Howard B, Ockene J (2003) The Women’s Health Initiative dietary
modification trial: overview and baseline characteristics of participants.
Ann Epidemiol 13: S87–S97
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ,
Adrian TE, Pour PM (2001) Prevention of pancreatic cancer induction in
hamsters by metformin. Gastroenterology 120: 1263–1270
Sierra-Johnson J, Johnson BD, Bailey KR, Turner ST (2004) Relationships
between insulin sensitivity and measures of body fat in asymptomatic
men and women. Obes Res 12: 2070–2077
Sinner PJ, Schmitz KH, Anderson KE, Folsom AR (2005) Lack of
association of physical activity and obesity with incident pancreatic
cancer in elderly women. Cancer Epidemiol Biomarkers Prev 14:
1571–1573
Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003)
The Women’s Health Initiative postmenopausal hormone trials:
overview and baseline characteristics of participants. Ann Epidemiol
13: S78–S86
Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR,
Virtamo J, Albanes D (2005) Insulin, glucose, insulin resistance, and
pancreatic cancer in male smokers. JAMA 294: 2872–2878
Tanko LB, Bruun JM, Alexandersen P, Bagger YZ, Richelsen B,
Christiansen C, Larsen PJ (2004) Novel associations between
bioavailable estradiol and adipokines in elderly women with different
phenotypes of obesity: implications for atherogenesis. Circulation 110:
2246–2252
Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM (2001)
Waist circumference vs body mass index for prediction of disease
risk in postmenopausal women. Int J Obes Relat Metab Disord 25:
1183–1188
Wang F, Herrington M, Larsson J, Permert J (2003) The relationship
between diabetes and pancreatic cancer. Mol Cancer 2: 4
Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF,
Adam HO (2001) A prospective study of obesity and cancer risk
(Sweden). Cancer Causes Control 12: 13–21
Appendix
SHORT LIST OF WHI INVESTIGATORS
Programme Office: (National Heart, Lung, and Blood Institute,
Bethesda, MD, USA) Elizabeth Nabel, Jacques Rossouw, Shari Ludlam,
Linda Pottern, Joan McGowan, Leslie Ford, and Nancy Geller.
Clinical Coordinating Center: (Fred Hutchinson Cancer
Research Center, Seattle, WA, USA)
Ross Prentice, Garnet Anderson, Andrea LaCroix, Charles L
Kooperberg, Ruth E Patterson, Anne McTiernan; (Wake Forest
University School of Medicine, Winston-Salem, NC, USA) Sally
Shumaker; (Medical Research Labs, Highland Heights, KY, USA)
Evan Stein; (University of California at San Francisco, San
Francisco, CA, USA) Steven Cummings.
Clinical Centers: (Albert Einstein College of Medicine, Bronx,
NY, USA) Sylvia Wassertheil-Smoller; (Baylor College of Medicine,
Houston, TX, USA) Aleksandar Rajkovic; (Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA, USA) JoAnn
Manson; (Brown University, Providence, RI, USA) Annlouise R.
Assaf; (Emory University, Atlanta, GA, USA) Lawrence Phillips;
(Fred Hutchinson Cancer Research Centre, Seattle, WA, USA)
Shirley Beresford; (George Washington University Medical Center,
Washington, DC, USA) Judith Hsia; (Los Angeles Biomedical
Research Institute at Harbor-UCLA Medical Center, Torrance, CA,
USA) Rowan Chlebowski; (Kaiser Permanente Center for Health
Research, Portland, OR, USA) Evelyn Whitlock; (Kaiser Perma-
nente Division of Research, Oakland, CA, USA) Bette Caan;
(Medical College of Wisconsin, Milwaukee, WI, USA) Jane
Morley Kotchen; (MedStar Research Institute/Howard University,
Washington, DC, USA) Barbara V Howard; (Northwestern
University, Chicago/Evanston, IL, USA) Linda Van Horn;
(Rush Medical Center, Chicago, IL, USA) Henry Black; (Stanford
Prevention Research Center, Stanford, CA, USA) Marcia L
Stefanick; (State University of New York at Stony Brook, Stony
Brook, NY, USA) Dorothy Lane; (The Ohio State University,
Columbus, OH, USA) Rebecca Jackson; (University of Alabama at
Birmingham, Birmingham, AL, USA) Cora E Lewis; (University of
Arizona, Tucson/Phoenix, AZ, USA) Tamsen Bassford; (University
at Buffalo, Buffalo, NY, USA) Jean Wactawski-Wende; (University
of California at Davis, Sacramento, CA, USA) John Robbins;
(University of California at Irvine, CA, USA) F Allan Hubbell;
(University of California at Los Angeles, Los Angeles, CA, USA)
Howard Judd; (University of California at San Diego, LaJolla/Chula
Vista, CA, USA) Robert D Langer; (University of Cincinnati,
Cincinnati, OH, USA) Margery Gass; (University of Florida,
Gainesville/Jacksonville, FL, USA) Marian Limacher; (University
of Hawaii, Honolulu, HI, USA) David Curb; (University of Iowa,
Iowa City/Davenport, IA, USA) Robert Wallace; (University of
Massachusetts/Fallon Clinic, Worcester, MA, USA) Judith Ockene;
(University of Medicine and Dentistry of New Jersey, Newark, NJ,
USA) Norman Lasser; (University of Miami, Miami, FL, USA)
Mary Jo O’Sullivan; (University of Minnesota, Minneapolis, MN)
Karen Margolis; (University of Nevada, Reno, NV, USA) Robert
Brunner; (University of North Carolina, Chapel Hill, NC, USA)
Gerardo Heiss; (University of Pittsburgh, Pittsburgh, PA, USA)
Lewis Kuller; (University of Tennessee, Memphis, TN, USA) Karen
C Johnson; (University of Texas Health Science Center, San
Antonio, TX, USA) Robert Brzyski; (University of Wisconsin,
Madison, WI, USA) Gloria E Sarto; (Wake Forest University School
of Medicine, Winston-Salem, NC, USA) Denise Bonds; (Wayne
State University School of Medicine/Hutzel Hospital, Detroit, MI,
USA) Susan Hendrix.
Obesity and pancreatic cancer risk
J Luo et al
531
British Journal of Cancer (2008) 99(3), 527–531 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y